Trial · NCT01426763
Results by group118
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 118
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | Number of participants with adverse events | 6 | participants | |
| Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study | SC CINRYZE With rHuPH20 Dose Level 2 | Number of participants with adverse events | 5 | participants | |
| Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | Number of participants with injection site reactions | 6 | participants | |
| Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study | SC CINRYZE With rHuPH20 Dose Level 2 | Number of participants with injection site reactions | 5 | participants | |
| Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | Number of participants who discontinued study drug | 0 | participants | |
| Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study | SC CINRYZE With rHuPH20 Dose Level 2 | Number of participants who discontinued study drug | 0 | participants | |
| Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | Number of participants who withdrew from the study | 0 | participants | |
| Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study | SC CINRYZE With rHuPH20 Dose Level 2 | Number of participants who withdrew from the study | 0 | participants | |
| Mean Change C1 Inhibitor (C1INH) | Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1 | 0 Hour (h) | 0.0248 | Standard Deviation 0.0565 | g/L |
| Mean Change C1 Inhibitor (C1INH) | SC CINRYZE With rHuPH20 Dose Level 2 | 0 Hour (h) | 0.00483 | Standard Deviation 0.00904 | g/L |
| Mean Change C1 Inhibitor (C1INH) | Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1 | 1 hour (h) post Dose 1 | 0.0273 | Standard Deviation 0.065 | g/L |
| Mean Change C1 Inhibitor (C1INH) | SC CINRYZE With rHuPH20 Dose Level 2 | 1 hour (h) post Dose 1 | 0.00383 | Standard Deviation 0.00417 | g/L |
| Mean Change C1 Inhibitor (C1INH) | Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1 | 2 h post Dose 1 | 0.0302 | Standard Deviation 0.0637 | g/L |
| Mean Change C1 Inhibitor (C1INH) | SC CINRYZE With rHuPH20 Dose Level 2 | 2 h post Dose 1 | 0.008 | Standard Deviation 0.0123 | g/L |
| Mean Change C1 Inhibitor (C1INH) | Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1 | 3 h post Dose 1 | 0.0275 | Standard Deviation 0.0602 | g/L |
| Mean Change C1 Inhibitor (C1INH) | SC CINRYZE With rHuPH20 Dose Level 2 | 3 h post Dose 1 | 0.0095 | Standard Deviation 0.00729 | g/L |
| Mean Change C1 Inhibitor (C1INH) | Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1 | 4 h post Dose 1 | 0.0382 | Standard Deviation 0.0652 | g/L |
| Mean Change C1 Inhibitor (C1INH) | SC CINRYZE With rHuPH20 Dose Level 2 | 4 h post Dose 1 | 0.011 | Standard Deviation 0.00537 | g/L |
| Mean Change C1 Inhibitor (C1INH) | Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1 | 6 h post Dose 1 | 0.0398 | Standard Deviation 0.0599 | g/L |
| Mean Change C1 Inhibitor (C1INH) | SC CINRYZE With rHuPH20 Dose Level 2 | 6 h post Dose 1 | 0.020 | Standard Deviation 0.00678 | g/L |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01426763/results